Curium's radioligand therapy Bexlutry has been approved in the US as a generic – or 'radioligand equivalent' (RLE) – of ...

Patients in the EU with rare disease thymidine kinase 2 deficiency (TK2d) have their first approved therapy, UCB's Kygevvi, after the European Commission cleared the drug "under exceptional ...

AI company Anthropic has launched a new large language model (LLM) – Claude Fable 5 – claiming its capabilities as a tool for drug discovery and scientific research gives it a big lead over other ...

A pharmaceutical company sends a patient a reminder to refill a prescription. A specialty pharmacy calls to coordinate ...

On World Diabetes Day, Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug designed to delay the progression of type 1 diabetes (T1D). The EMA's human ...

GSK has continued its drive to bulk up its pipeline, taking global rights to a T-cell engager (TCE) for multiple myeloma, ...

The planned IPO comes after Electra raised $183 million in a Series C that completed last October, as it started dosing ...

Khougazian – who is currently at investment group Flagship Pioneering – will take over as CEO of Chiesi on 15th October, ...

The organisation should not automatically double simply because revenue does. These are directional ranges, not rules, but they expose an important principle: headcount growth should normally lag ...

RNA-targeted small molecules are rapidly emerging as one of the most exciting areas in drug discovery, with growing clinical validation demonstrating the potential to address historically undruggable ...

The Danish Group stated that the new corporate culture – dubbed 'The Novo Way' – centres around four Cs; namely, customer ...

Hard on the heels of a big disappointment in its cardiovascular pipeline, Novartis has suffered another – this time for its highly anticipated neuromuscular disease therapy del-desiran. The company's ...